FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OM	D /	חח		۸ / ۸
	IB 4	۱PP	ĸ.	WA

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Farrell Michael J.  (Last) (First) (Middle)  RESMED INC.			2. Issuer Name <b>and</b> Ticker or Trading Symbol RESMED INC [ RMD ]		tionship of Reporting Person all applicable) Director	10% Owner Other (specify below)	
		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/13/2019	X	Officer (give title below)  Chief Executive		
0001 CDECTRUM CENTER DI VID		92123	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	idual or Joint/Group Filing (C Form filed by One Report Form filed by More than C	ing Person	
(City)	(State)	(Zip)					

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
ResMed Common Stock	05/13/2019		<b>M</b> <sup>(1)</sup>		6,651	A	\$43.63	292,988(2)	D	
ResMed Common Stock	05/13/2019		S <sup>(1)</sup>		6,391	D	\$109.699(3)	286,597	D	
ResMed Common Stock	05/13/2019		S <sup>(1)</sup>		260	D	\$110.247(4)	286,337	D	
ResMed Common Stock								10,340	I	Lisette and Michael Farrell Family Trust

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$43.63	05/13/2019		M <sup>(1)</sup>			6,651	03/01/2014 <sup>(5)</sup>	03/01/2020	ResMed Commmon Stock	6,651	\$0	59,855	D	

## Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan.
- $2.\ Includes\ 54.834\ shares\ of\ ResMed\ stock\ purchased\ on\ April\ 30,\ 2019,\ through\ the\ ResMed\ Employee\ Stock\ Purchase\ Plan.$
- 3. This transaction was executed in multiple trades at prices ranging from \$109.17 to \$110.16. The price reported above reflects the weighted average sale price.
- 4. This transaction was executed in multiple trades at prices ranging from \$109.17 to \$110.29. The price reported above reflects the weighted average sale price.
- 5. Represents date options first became exercisable. Options vest 1/3 per year.

Michael J. Farrell, Chief <u>Executive Officer</u> 05/

05/14/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.